Literature DB >> 10319243

Safety of treatment with oral anticoagulants in the elderly. A systematic review.

B A Hutten1, A W Lensing, R A Kraaijenhagen, M H Prins.   

Abstract

Oral anticoagulants have documented efficacy for many indications and are widely used in elderly patients. However, there is concern about whether this treatment induces an excess of major bleeding in elderly patients. In this systematic review, the incidence of oral anticoagulant-related major bleeding among elderly patients was determined. A total of 58 reports were identified that evaluated an oral anticoagulant, included patients with a mean age of at least 60 years, and provided data on the occurrence of major bleeding or provided separate data on the occurrence of major bleeding in elderly versus younger patients. In 50 studies no age differentiation was given. Although the incidence of bleeding complications varied, a trend towards increased bleeding with increasing age was shown in patients with major orthopaedic surgery and cardiac diseases. In the 8 articles that provided separate data on the occurrence of bleeding in different age categories, there was a clear tendency towards a 2-fold increase in bleeding in elderly patients. These findings emphasise the need for caution in the use of oral anticoagulants in elderly patients. However, the decision to start oral anticoagulant treatment should be based on an evaluation of the risk/benefit balance on a careful patient-by-patient basis. In general, if oral anticoagulant treatment is started, the lowest possible effective International Normalised Ratios (INR) should be selected and regular monitoring should be done to avoid over-anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319243     DOI: 10.2165/00002512-199914040-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  72 in total

1.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

2.  Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.

Authors:  C Morocutti; G Amabile; F Fattapposta; A Nicolosi; S Matteoli; M Trappolini; G Cataldo; G Milanesi; M Lavezzari; F Pamparana; S Coccheri
Journal:  Stroke       Date:  1997-05       Impact factor: 7.914

3.  Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort.

Authors:  F H Steffensen; K Kristensen; E Ejlersen; J F Dahlerup; H T Sørensen
Journal:  J Intern Med       Date:  1997-12       Impact factor: 8.989

4.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

5.  Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty.

Authors:  D D Do; F Mahler
Journal:  Radiology       Date:  1994-11       Impact factor: 11.105

6.  Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis.

Authors:  T Lundström; L Rydén
Journal:  J Intern Med       Date:  1989-02       Impact factor: 8.989

7.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

8.  Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin.

Authors:  D B Petitti; B L Strom; K L Melmon
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

9.  Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

Authors:  J N Saour; J O Sieck; L A Mamo; A S Gallus
Journal:  N Engl J Med       Date:  1990-02-15       Impact factor: 91.245

10.  Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole.

Authors:  J H Chesebro; V Fuster; L R Elveback; D C McGoon; J R Pluth; F J Puga; R B Wallace; G K Danielson; T A Orszulak; J M Piehler; H V Schaff
Journal:  Am J Cardiol       Date:  1983-05-15       Impact factor: 2.778

View more
  18 in total

Review 1.  Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Authors:  Alina Andras; Adriano Sala Tenna; Marlene Stewart
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

2.  Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.

Authors:  E Comets; B Diquet; S Legrain; M-G Huisse; A Godon; C Bruhat; M-P Chauveheid; S Delpierre; X Duval; G Berrut; C Verstuyft; M-C Aumont; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-05       Impact factor: 6.875

Review 3.  Stroke prevention in atrial fibrillation: putting the guidelines into practice.

Authors:  Jonathan Mant; Duncan Edwards
Journal:  Drugs Aging       Date:  2010-11-01       Impact factor: 3.923

4.  Development of geriatric competencies for emergency medicine residents using an expert consensus process.

Authors:  Teresita M Hogan; Eve D Losman; Christopher R Carpenter; Karen Sauvigne; Cheryl Irmiter; Linda Emanuel; Rosanne M Leipzig
Journal:  Acad Emerg Med       Date:  2010-03       Impact factor: 3.451

Review 5.  Management of venous thromboembolism in the elderly.

Authors:  Alex C Spyropoulos; Geno Merli
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Relationship between diet and anticoagulant response to warfarin: a factor analysis.

Authors:  Silvia Maria Custódio das Dôres; Sarah L Booth; Ligia Araújo Martini; Ligia Aújo Martini; Victor Hugo de Carvalho Gouvêa; Carlos Roberto Padovani; Francisco Humberto de Abreu Maffei; Alvaro Oscar Campana; Sérgio Alberto Rupp de Paiva
Journal:  Eur J Nutr       Date:  2007-03-13       Impact factor: 5.614

Review 7.  Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Authors:  Celeste B Burness; Caroline M Perry
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

8.  Complicated rheumatic mitral stenosis presenting in an elderly patient and the challenges in its management.

Authors:  Swapnil Ganeshpure; Gaurang Nandkishor Vaidya; Vipul Gattani
Journal:  BMJ Case Rep       Date:  2012-12-05

Review 9.  Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.

Authors:  Michael Makris; Joost J van Veen; Rhona Maclean
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

Review 10.  Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management.

Authors:  Eric Pautas; Isabelle Gouin-Thibault; Matthieu Debray; Pascale Gaussem; Virginie Siguret
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.